The new epidemiology of nosocomial bacterial infections in cirrhosis: Therapeutical implications

Hepatology International

Volumn 7, Issue 1, 2013, Pages 72-79

  Acevedo, Juan ^a,b,c,d   Silva, Aníbal ^a,b,c   Prado, Verónica ^a,b,c   Fernández, Javier ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Hospital Sant Jaume de Calella   (Spain)

Author keywords

Liver cirrhosis; Multiresistant bacteria; Nosocomial infection

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; NORFLOXACIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CELLULITIS; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DEATH; DRUG EFFICACY; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; LIVER CIRRHOSIS; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; SEPSIS; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84875270171     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-012-9396-x     Document Type: Review

References (52)

1. J Fernández T Gustot 2012 Management of bacterial infections in cirrhosis J Hepatol 56 Suppl 1 S1 S12 22300459 10.1016/S0168-8278(12)60002-6
2. T Gustot F Durand D Lebrec, et al. 2009 Severe sepsis in cirrhosis Hepatology 50 2022 2033 19885876 10.1002/hep.23264 1:CAS:528:DC%2BD1MXhs1SjurnP
3. P Tandon G Garcia-Tsao 2008 Bacterial infections, sepsis, and multiorgan failure in cirrhosis Semin Liver Dis 28 26 42 18293275 10.1055/s-2008-1040319 1:CAS:528:DC%2BD1cXjvFCju7c%3D
4. J Fernández M Navasa J Gomez, et al. 2002 Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis Hepatology 35 140 148 11786970 10.1053/jhep.2002.30082
5. J Fernández J Acevedo M Castro, et al. 2012 Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study Hepatology 55 5 1551 1561 22183941 10.1002/hep.25532
6. V Arvaniti G D'Amcio G Fede, et al. 2010 Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis Gastroenterology 139 1246 1256 20558165 10.1053/j.gastro.2010.06.019
7. MG Foreman DM Mannino M Moss 2003 Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey Chest 124 1016 1020 12970032 10.1378/chest.124.3.1016
8. A Plessier MH Denninger Y Consigny, et al. 2003 Coagulation disorders in patients with cirrhosis and severe sepsis Liver Int 23 440 448 15002397 10.1111/j.1478-3231.2003.00870.x
9. B Bernard JD Grangé EN Khac, et al. 1999 Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis Hepatology 29 1655 1661 10347104 10.1002/hep.510290608 1:CAS:528:DyaK1MXjvFOms7g%3D
10. H Yoshida T Hamada S Inuzuka, et al. 1993 Bacterial infection in cirrhosis, with and without hepatocellular carcinoma Am J Gastroenterol 88 2067 2071 8249975 1:STN:280:DyaK2c%2FntVOrug%3D%3D
11. J Llach A Rimola M Navasa, et al. 1992 Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration Hepatology 16 724 727 1505916 10.1002/hep.1840160318 1:STN:280:DyaK38zntF2msg%3D%3D
12. P Ginès A Rimola R Planas, et al. 1990 Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial Hepatology 12 716 724 2210673 10.1002/hep.1840120416
13. JY Song SJ Jung CW Park, et al. 2006 Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired J Korean Med Sci 21 666 671 16891810 10.3346/jkms.2006.21.4. 666
14. HS Cheong C Kang JA Lee, et al. 2009 Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis Clin Infect Dis 48 1230 1236 19302016 10.1086/597585
15. X Ariza J Castellote J Lora-Tamayo, et al. 2012 Risk factors for resistance to ceftriaxone and its impact on mortality in community, healthcare and nosocomial spontaneous bacterial peritonitis J Hepatol 56 825 832 22173153 10.1016/j.jhep.2011.11.010 1:CAS:528:DC%2BC38Xktlaqt74%3D
16. B Campillo C Dupeyron JP Richardet, et al. 1998 Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin Clin Infect Dis 26 1066 1070 9597225 10.1086/520273 1:STN:280:DyaK1c3lvFGisQ%3D%3D
17. M Merli C Lucidi V Giannelli, et al. 2010 Cirrhotic patients are at risk for health care-associated bacterial infections Clin Gastroenterol Hepatol 8 979 985 20621200 10.1016/j.cgh.2010.06.024
18. HE Wasmuth D Kunz E Yagmur, et al. 2005 Patients with acute on chronic liver display "sepsis-like" immune paralysis J Hepatol 42 195 201 15664244 10.1016/j.jhep.2004.10.019 1:CAS:528:DC%2BD2MXmvFSqug%3D%3D
19. RP Mookerjee V Stadlbauer S Lidder, et al. 2007 Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome Hepatology 46 831 840 17680644 10.1002/hep.21737 1:CAS:528: DC%2BD2sXhtFWhsrvJ
20. R Wiest G Garcia-Tsao 2005 Bacterial translocation (BT) in cirrhosis Hepatology 41 422 433 15723320 10.1002/hep.20632 1:CAS:528:DC%2BD2MXisFCku7g%3D
21. YH Park HC Lee HG Song, et al. 2003 Recent increase in antibiotic-resistant microorganism in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea J Gastroenterol Hepatol 18 927 933 12859722 10.1046/j.1440-1746.2003.03086.x
22. KH Song JH Jeon WB Park, et al. 2009 Clinical outcomes of spontaneous bacterial peritonitis due to extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case-control study BMC Infect Dis 9 41 46 19361340 10.1186/1471-2334-9-41
23. CI Kang SH Kim WB Park, et al. 2004 Clinical outcomes of bacteremic spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella pneumoniae Korean J Intern Med 19 160 164 15481607
24. ME Falagas DE Karageorgopoulos 2009 Extended-spectrum β-lactamase-producing organism J Hosp Infect 73 345 354 19596491 10.1016/j.jhin.2009.02.021 1:STN:280:DC%2BD1MjmsFersA%3D%3D
25. GE Stein 2005 Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures Pharmacotherapy 25 44S 54S 16178675 10.1592/phco.2005.25.10part2.44S 1:CAS:528:DC%2BD2MXhtFKnsrjF
26. DL Paterson WC Ko A Von Gottberg, et al. 2004 International prospective study of Klebsiella pneumoniae bacteremia: implications of Extended-spectrum β-lactamase production in nosocomial infections Ann Intern Med 140 26 32 14706969
27. PO Depuydt DM Vandijck MA Bekaert, et al. 2008 Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated- pneumonia Crit Care 12 R142 19014695 10.1186/cc7119
28. B Campillo JP Richardet T Kheo, et al. 2002 Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection Clin Infect Dis 35 1 10 12060868 10.1086/340617
29. F Bert M Andreu F Durand, et al. 2003 Nosocomial and community-acquired spontaneous bacterial peritonitis: comparative microbiology and therapeutic implications Eur J Clin Microbiol Infect Dis 22 10 15 12582738 1:STN:280:DC%2BD3s%2FntFGjtQ%3D%3D
30. F Cereto X Herranz E Moreno, et al. 2008 Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis Eur J Gastroenterol Hepatol 20 924 929 18794608 10.1097/MEG.0b013e3282fc7390 1:CAS:528:DC%2BD1cXhtVygtbzK
31. S Angeloni C Leboffe A Parente, et al. 2008 Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice World J Gastroenterol 14 2757 2762 18461661 10.3748/wjg.14.2757 1:CAS:528:DC%2BD1cXhtF2mtLrE
32. J Heo YS Seo HJ Yim, et al. 2009 Clinical features and prognosis of spontaneous bacterial peritonitis in Korean patients with liver cirrhosis: a multicenter retrospective study Gut Liver 3 197 204 20431746 10.5009/gnl.2009.3.3.197
33. T Yakar M Güçlü E Serin, et al. 2009 A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis Dig Dis Sci 55 1149 1154 19424797 10.1007/s10620-009-0825-1
34. L Piroth A Pechinot A Minello, et al. 2009 Bacterial epidemiology and antimicrobial resistance in ascetic fluid: a 2-year retrospective study Scand J Infect Dis 37 2 8
35. A Umgelter W Reindl M Miedaner, et al. 2009 Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis Infection 37 2 8 19169633 10.1007/s15010-008-8060-9 1:STN:280:DC%2BD1M3gtlKhtw%3D%3D
36. G Cornaglia H Giamarellou GM Rossolini 2011 Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis 11 381 393 21530894 10.1016/S1473-3099(11)70056-1 1:CAS:528:DC%2BC3MXlsVGntL4%3D
37. R Cantón M Akóva Y Carmeli, et al. 2012 Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe Clin Microbiol Infect 18 413 431 22507109 10.1111/j.1469-0691.2012.03821.x
38. Piano S, Romano A, Rosi S et al. (2012) Spontaneous bacterial peritonitis due to carbapenemase-producing Klebsiella pneumoniae: the last therapeutic challenge. Eur J Gastroenterol Hepatol (Epub ahead of print).
39. A Apisarnthanarak TC Bailey VJ Fraser 2008 Duration of stool colonization in patients infected with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae Clin Infect Dis 46 1322 1323 18444877 10.1086/533475
40. OK Azap H Arslan K Serefhanoǧlu, et al. 2010 Risk factors for extended-spectrum β-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections Clin Microbiol Infect 16 147 151 19689464 10.1111/j.1469-0691.2009.02941.x 1:CAS:528: DC%2BC3cXitlKqt7k%3D
41. R Ben-Ami J Rodríguez-Baño H Arslan, et al. 2009 A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients Clin Infect Dis 49 682 690 19622043 10.1086/604713
42. J Rodríguez-Baño E Picón P Gijón, et al. 2010 Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis Clin Infect Dis 50 40 48 19995215 10.1086/649537
43. J Rodríguez-Baño E Picón P Gijón, et al. 2010 Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli J Clin Microbiol 48 1726 1731 20181897 10.1128/JCM.02353-09
44. J Felisart A Rimola V Arroyo, et al. 1985 Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections Hepatology 5 457 462 3888810 10.1002/hep.1840050319 1:STN:280:DyaL2M3gsFOrug%3D%3D
45. A Rimola JM Salmerón G Clemente, et al. 1995 Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study Hepatology 21 674 679 7875666 10.1002/hep.1840210312 1:STN:280:DyaK2M7otVyhtA%3D%3D
46. A Rimola G García-Tsao M Navasa, et al. 2000 Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club J Hepatol 32 142 153 10673079 10.1016/S0168-8278(00) 80201-9 1:STN:280:DC%2BD3c7jsFKgtg%3D%3D
47. European Association for the Study of the Liver 2010 EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 397 417 10.1016/j.jhep.2010.05.004
48. BA Runyon AASLD Practice Guidelines Committee 2009 Management of adult patients with ascites due to cirrhosis: an update Hepatology 49 2087 2107 19475696 10.1002/hep.22853
49. J Ortiz MC Vila G Soriano, et al. 1999 Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients Hepatology 29 1064 1069 10094947 10.1002/hep.510290406 1:CAS:528:DyaK1MXisVKgsLw%3D
50. Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. London: Churchill Livingston Elsevier; 2012.
51. S Blot 2008 Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units Clin Microbiol Infect 14 5 13 17944969 10.1111/j.1469-0691.2007.01835.x 1:STN:280:DC%2BD2sjmtV2htw%3D%3D
52. E Tasina AB Haidich S Kokkali, et al. 2011 Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis Lancet Infect Dis 11 834 844 21784708 10.1016/S1473-3099(11)70177-3 1:CAS:528:DC%2BC3MXhsVSksL%2FO